<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00633529</url>
  </required_header>
  <id_info>
    <org_study_id>EMR 200068-200</org_study_id>
    <nct_id>NCT00633529</nct_id>
  </id_info>
  <brief_title>Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC</brief_title>
  <official_title>Open-Label Phase 1b Study of Erlotinib Plus Bevacizumab and IMO-2055 in Patients With Non-Small Cell Lung Cancer Who Have Progressed Following Initial Chemotherapy for Advanced or Metastatic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety of the proposed Phase II dosage of the investigational drug IMO 2055&#xD;
      when combined with erlotinib and bevacizumab in patients with previously treated advanced&#xD;
      NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1b study of escalating doses of weekly subcutaneous IMO-2055 combined with fixed&#xD;
      standard dose regimens of oral erlotinib (daily) and IV bevacizumab (every 3 weeks) in&#xD;
      patients with previously treated advanced NSCLC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the recommended dosage of IMO-2055 when combined with erlotinib and bevacizumab in patients with AJCC stage 3 or 4 histologically proven non-small cell lung cancer (NSCLC).</measure>
    <time_frame>Assessed on a weekly basis at patient visits.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of weekly IMO-2055 combined with erlotinib plus bevacizumab using NCI CTCAE version 3.</measure>
    <time_frame>Assessed on a weekly basis at patient visits.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate potential drug-drug interactions via a PK study, specifically the effect of IMO-2055 on the PK of bevacizumab and the PK of erlotinib and also the effect of bevacizumab and erlotinib on the PK of IMO-2055.</measure>
    <time_frame>Assessed on a weekly basis at patient visits.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate potential signs of efficacy using RECIST response rate in measurable patients and PFS in all patients.</measure>
    <time_frame>Assessed every six weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm: triple combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMO-2055</intervention_name>
    <description>0.08, 0.16, or 0.32 mg/kg SC (subcutaneous) on days 1,8,and 15 of every 21 day cycle until evidence of progressive disease, unacceptable treatment-related toxicities, withdrawal of patient consent and/or Investigator decision to withdraw study therapy with documented reason, whichever occurs first.</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
        Patients must satisfy all the following inclusion criteria in order to be eligible for the&#xD;
        study:&#xD;
&#xD;
          1. Signed written informed consent&#xD;
&#xD;
          2. AJCC stage 3 or 4 histologically proven NSCLC not amenable to curative therapy and for&#xD;
             whom erlotinib and bevacizumab therapy would be appropriate&#xD;
&#xD;
          3. Radiological assessment within 21 days prior to inclusion, if measurable disease is&#xD;
             present&#xD;
&#xD;
          4. Age ≥ 18 years&#xD;
&#xD;
          5. ECOG performance status 0 or 1&#xD;
&#xD;
          6. Patient has received at least one standard platinum-containing chemotherapy regimen&#xD;
             appropriate for his/her lung cancer, in the opinion of the investigator, prior to&#xD;
             enrollment.&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
        Patients with any of the following will be excluded from participation in the study:&#xD;
&#xD;
        Disease&#xD;
&#xD;
          1. Squamous cell carcinoma, except for patients with no intrathoracic disease or small&#xD;
             peripheral lesions only.&#xD;
&#xD;
          2. Known central nervous system (CNS) metastases (Note: patients with brain metastases&#xD;
             which have been controlled for ≥ 4 months without the use of steroid are eligible).&#xD;
&#xD;
             Prior Treatments&#xD;
&#xD;
          3. Less than 4 weeks between registration and the last receipt of chemotherapy,&#xD;
             biotherapy, radiotherapy or major surgery&#xD;
&#xD;
          4. Concurrent or planned hormonal agents such as replacement therapy, oral&#xD;
             contraceptives, or anti-cancer therapy, e.g. Megace. (A prior history of such therapy&#xD;
             is not exclusionary.)&#xD;
&#xD;
          5. Administration of any investigational agent (therapeutic or diagnostic), including any&#xD;
             investigational compound for the treatment of NSCLC, within 4 weeks prior to first&#xD;
             study dosing Other Concomitant Medications&#xD;
&#xD;
          6. High dose oral or intravenous corticosteroids. (Note: topical, inhaled and&#xD;
             intra-articular corticosteroids are allowed. Prophylactic antihistamines are allowed&#xD;
             before administration of bevacizumab&#xD;
&#xD;
          7. Use of any medication which is a strong inhibitor or inducer of cytochrome P450&#xD;
             isoform CYP3A4 (see Appendix 5)&#xD;
&#xD;
          8. Therapeutic dosing with warfarin &gt;1 mg/day&#xD;
&#xD;
          9. Chronic daily use of aspirin (&gt; 325 mg/day) or other full-dose NSAIDs with&#xD;
             anti-platelet activity&#xD;
&#xD;
         10. Inability to take oral medication or requirement for IV alimentation or total&#xD;
             parenteral nutrition with lipids, or prior surgical procedures affecting absorption&#xD;
             Laboratory&#xD;
&#xD;
         11. The following laboratory results, within 10 days of first study drug administration:&#xD;
&#xD;
               -  Hemoglobin ≤ 9.0 g/dL Absolute neutrophil count ≤ 1.5 x 109/L Platelet count ≤&#xD;
                  100 x 109/L&#xD;
&#xD;
               -  International Normalized Ratio (INR) &gt; 1.3 (only if the subject is on warfarin [&lt;&#xD;
                  1 mg per day]) during 28 days prior to enrollment.&#xD;
&#xD;
               -  aPTT &gt; Upper Limit of Normal (ULN) during 28 days prior to enrollment.&#xD;
&#xD;
               -  Serum creatinine ≥ 1.5 x ULN and creatinine clearance (by Cockcroft-Gault&#xD;
                  formula) &lt;60 mL/min&#xD;
&#xD;
               -  Serum bilirubin ≥ 1.5 x ULN&#xD;
&#xD;
               -  Proteinuria: UPC ≥ 1.0 or ≥ 2+ proteinuria by urine dipstick, unless a 24-hour&#xD;
                  urine demonstrates &lt;1.0 g/24 hours&#xD;
&#xD;
               -  ALT or AST ≥ 2.5 x ULN (≥ 5 x ULN if liver metastases)&#xD;
&#xD;
               -  Alkaline phosphatase ≥ 2.5 x ULN&#xD;
&#xD;
               -  Albumin ≤ 2.5 g/L&#xD;
&#xD;
               -  Women of child bearing potential: positive pregnancy test (serum). Other&#xD;
                  Conditions or Procedures&#xD;
&#xD;
         12. Any clinically significant adverse events from any prior chemotherapy, surgery or&#xD;
             radiotherapy which has not yet resolved to CTCAE v3.0 grade ≤ 1&#xD;
&#xD;
         13. Known hypersensitivity to any oligodeoxynucleotide (ODN), EGFR-inhibitor or&#xD;
             bevacizumab&#xD;
&#xD;
         14. Serious, non-healing wound, ulcer or bone fracture&#xD;
&#xD;
         15. Patients with a history or current neoplasm other than the entry diagnosis, except for&#xD;
             curatively treated non-melanoma skin cancer or carcinoma in situ of the cervix and&#xD;
             except for other cancers treated for cure and with a disease-free survival greater&#xD;
             than 5 years.&#xD;
&#xD;
         16. Pregnant or breast-feeding women&#xD;
&#xD;
         17. Men or women of childbearing potential who refuse or who are unable to use an&#xD;
             acceptable means of contraception&#xD;
&#xD;
         18. History of clinically significant hemoptysis within 3 months prior to registration&#xD;
             unless definitively treated with surgery or radiation&#xD;
&#xD;
         19. Any medical conditions that would impose excessive risk to the patient, such as&#xD;
             uncontrolled hypertension (systolic &gt;150 mmHg or diastolic &gt;100 mmHg per JNC 7&#xD;
             guidelines, congestive heart failure NYHA Class 2-4, uncontrolled or unstable angina,&#xD;
             myocardial infarction within the previous 6 months, ventricular arrhythmia, infection&#xD;
             requiring parental or oral anti-infective treatment, any altered mental status or any&#xD;
             psychiatric condition that would interfere with understanding the informed consent,&#xD;
             uncontrolled seizures, chronic hepatitis or cirrhosis, known human immunodeficiency&#xD;
             virus (HIV) infection, known hepatitis B surface antigen (HBsAg) positive or&#xD;
             uncontrolled diabetes. (Note: testing for HIV infection of HBsAg is not part of the&#xD;
             screening assessments performed by the central laboratory).&#xD;
&#xD;
         20. Pre-existing autoimmune or antibody-mediated diseases, including, but not limited to,&#xD;
             the following: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis,&#xD;
             Sjogren's syndrome and autoimmune thrombocytopenia&#xD;
&#xD;
         21. Evidence of bleeding diathesis or coagulopathy or other serious or acute internal&#xD;
             bleeding within 6 months prior to registration&#xD;
&#xD;
         22. CNS bleeding; history or clinical evidence of CNS stroke (hemorrhagic or thrombotic)&#xD;
             within the last 6 months&#xD;
&#xD;
         23. History of allogeneic organ transplant&#xD;
&#xD;
         24. Brain biopsy within 12 weeks of first study dosing&#xD;
&#xD;
         25. Minor surgical procedure, central venous catheter placement, fine needle aspirations&#xD;
             or core biopsy within 7 days prior to first study dosing&#xD;
&#xD;
         26. Anticipation of need for a major surgical procedure during the course of the study&#xD;
             Other&#xD;
&#xD;
         27. Unwilling or unable to comply with the protocol for the duration of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phil Breitfeld, MD</last_name>
    <role>Study Director</role>
    <affiliation>EMD Serono</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Centers of Florida</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Indiana Cancer Centers</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology P.C.</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Medical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy and Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yakima Valley Memorial Hospital/North Shore Cancer Lodge</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Smith, D., P. Conkling, D. Richards, C. Alemany, T. Boyd, L. Garbo, D. Loesch, D. Wages, A. Bexon, J. Murphy. Phase 1 Study of the Toll-like Receptor (TLR9) Agonist, IMO-2055, Combined with Erlotinib and Bevacizumab in Patients with Advanced or Metastatic non-Small Cell Lung Cancer. ECCO-ESMO Annual Meeting, 2009. Abstract 9.148.</citation>
  </results_reference>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>March 3, 2008</study_first_submitted>
  <study_first_submitted_qc>March 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2008</study_first_posted>
  <last_update_submitted>October 21, 2013</last_update_submitted>
  <last_update_submitted_qc>October 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1b</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>Advanced or Metastatic Disease</keyword>
  <keyword>Prior chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

